Experimental HCV Drugs
Experimental HCV Drugs
Coverage of the 2013 International AIDS Society Conference
- Details
- Category: HIV Treatment
- Published on Saturday, 06 July 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013), June 30-July 3, in Kuala Lumpur, Malaysia.
Conference highlights include antiretroviral therapy strategies, treatment access, investigational agents for HIV and hepatitis C, management of HIV-related complications, biomedical HIV prevention, and HIV cure research.
HIVandHepatitis.com IAS 2013 conference section
7/6/13
IAS 2013: AbbVie Interferon-Free Hepatitis C Combo Works Well with Reduced Ribavirin Dose
- Details
- Category: Experimental HCV Drugs
- Published on Tuesday, 02 July 2013 00:00
- Written by Liz Highleyman
Hepatitis C patients who reduced their dose of ribavirin due to side effects nevertheless had a high likelihood of achieving sustained response when treated with an all-oral regimen containing 3 direct-acting antiviral agents, researchers reported at the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Gilead: Sofosbuvir for Hepatitis C Granted FDA Priority Review
- Details
- Category: HCV Treatment
- Published on Thursday, 13 June 2013 00:00
- Written by Gilead Sciences
Gilead's investigational nucleotide hepatitis C virus (HCV) polymerase inhibitor sofosbuvir (formerly GS-7977) has been given priority review status by the U.S. Food and Drug Administration, with a target date in early December, the company announced last week.
EASL 2013: NS5A Inhibitor GS-5816 Looks Good in Phase 1 Study, Now In Phase 2
- Details
- Category: HCV Treatment
- Published on Wednesday, 19 June 2013 00:00
- Written by Liz Highleyman
The next-generation HCV NS5A inhibitor GS-5816 demonstrated potent antiviral activity against a range of viral genotypes in a preclinical study presented at the recent EASL International Liver Congress in Amsterdam (EASL 2013), paving the way for a Phase 2 trial of GS-5816 plus sofosbuvir in an interferon-free dual regimen.
DDW 2013: Interferon-free Simeprevir + Sofosbuvir Suppresses Hepatitis C with or without Ribavirin
- Details
- Category: HCV Treatment
- Published on Thursday, 30 May 2013 00:00
- Written by Liz Highleyman
An all-oral regimen consisting of simeprevir (formerly TMC435) plus sofosbuvir, (formerly GS-7977), with or without ribavirin, produced an 8-week post-treatment cure for most prior null responders with genotype 1 hepatitis C in the COSMOS trial, according to a poster presented at the Digestive Disease Week meeting (DDW 2013) last week in Orlando.
Web Design and Development by